Engflag

Ermetin

Quick links to important sections

Ermetin

There is no image.

Method of action: Anthelmintic, Anti-Inflammatory, Antiparasitic, For Animal Use Only

Treatment option: Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ermetin

Property Description
Active Ingredient Ivermectin
Form Oral tablets, Topical (lotion, cream)
Pharmacological Class Anthelmintic, Antiparasitic (Avermectin class)
Common Use Eliminating parasitic infestations
Origin Semisynthetic derivative

What Kind of Medication is Ermetin?

Ermetin is a brand-specific, prescription-only pharmaceutical product containing the active substance Ivermectin, which is the core antiparasitic agent. It is formally classified as an anthelmintic belonging to the unique avermectin class of compounds. This classification establishes the drug's fundamental function: the targeted elimination of parasitic organisms. The active ingredient is clinically recognized for its broad-spectrum efficacy against both internal and external parasites.

Ivermectin: Composition, Origin, and Forms

The active ingredient, Ivermectin, is a semisynthetic derivative of a class of natural products called macrocyclic lactones. It is derived from the avermectins, which are originally isolated from the fermentation processes of the soil bacterium Streptomyces avermitilis. Ermetin is typically available as small, round oral tablets for systemic administration, but Ivermectin is also formulated into topical lotions and creams for specific cutaneous applications. The drug is differentiated by its oral and cutaneous routes of administration. Ivermectin's microbial origin underscores its unique biological source.

General Purpose of This Antiparasitic Agent

The general purpose of Ermetin is to disrupt the life cycle of parasitic organisms and clear active infestations. It acts as an endectocide, meaning it is effective against both internal (endo-) and external (ecto-) parasites. The mechanism involves selectively binding to communication channels on the parasite's nerve and muscle cells. This action induces paralysis and subsequent death of the organism. This specialized function enables the medication to effectively target parasitic organisms while maintaining safety for the human host.

Regulatory References

  1. National Institutes of Health (NIH)
  2. NIH MedlinePlus monograph

What side effects are possible with Ermetin?

Possible Side Effects and Safety Information

Ermetin (Ivermectin) is associated with an official safety profile categorized by frequency and the body system affected, based strictly on government regulatory documents. The profile distinguishes between direct drug effects and reactions linked to the death of parasites within the body.

Frequency-Classified Adverse Reactions

Adverse reactions that appear in official labeling are commonly grouped as follows:

  • Common: Adverse reactions listed as common include nausea, diarrhea, dizziness, headache, somnolence, fatigue, and pruritus (itching). These often appear as part of the body's systemic response.
  • Uncommon: Less frequent effects include confusion, vomiting, abdominal pain, tremor, and constipation.

Reactions linked to the Nervous System and Gastrointestinal Disorders are among the most frequently documented categories.

Serious Adverse Reactions and Contextual Safety

Regulatory documents highlight rare but serious adverse reactions and safety constraints:

  • Serious Reactions: Rare post-marketing reports include severe neurological events, such as seizures and encephalopathy, and major skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Co-Infection Risk: A significant safety constraint is the potential for severe neurological problems, including fatal encephalopathy, in patients being treated for onchocerciasis who also have a high microfilarial burden of Loa loa. This risk is typically relevant during the first three days after treatment.
  • Population-Specific Constraints: The oral tablets are not established as safe or effective in children weighing less than 15 kg. Use is also generally not recommended during pregnancy as safety has not been fully established, and the drug is known to pass into human milk during lactation.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Ermetin

The official regulatory profile for Ermetin (Ivermectin) details the documented clinical manifestations and required emergency procedures following overexposure.

Documented Overdose Manifestations

Category Officially Documented Clinical Signs
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain.
Nervous System Headache, dizziness, somnolence (drowsiness), tremor, ataxia (lack of coordination), asthenia (weakness).
Severe Outcomes Severe hypotension (low blood pressure), tachycardia, seizures, altered mental status, coma, and death are documented outcomes associated with massive overdose.

Immediate Regulatory Actions

Official labeling mandates that immediate medical attention must be sought, and emergency services (e.g., Poison Control Center) must be contacted immediately for any suspected overexposure. Medical help is required for any confirmed overdose or if severe symptoms such as seizures, severe hypotension, or loss of consciousness occur.

Clinical Management Profile

Regulatory information states that no specific antidote is known for Ivermectin overdose. Management is centered on symptomatic treatment and supportive therapy. Officially described procedural steps include the use of gastric emptying (such as lavage) followed by the administration of activated charcoal with a laxative to limit systemic absorption, often requiring hospital monitoring.

Therapeutic Uses of Ermetin

What Ermetin Treats: Main Uses and Benefits

Ermetin (Ivermectin) is commonly used to help manage a range of conditions presenting with parasitic activity, which provides supportive relief from the distressing symptoms they cause. These applications span several distinct therapeutic categories.

A major application of Ermetin is the management of systemic and intestinal parasitic infections, including threadworm (Strongyloides stercoralis) and tropical diseases like River Blindness (Onchocerciasis). Furthermore, it is applied in clinical settings for addressing external mite and lice infestations (scabies and pediculosis) and for supporting management of inflammatory lesions associated with rosacea.

Treatment is relevant when symptoms cluster into patterns of severe, unrelenting itching, gastrointestinal distress, or pronounced facial inflammation. In managing symptoms related to these conditions, the medication assists with maintaining functional stability and contributes to reducing the risk of associated complications, such as vision impairment.

Quick Fact: Addressing Systemic and Cutaneous Discomfort

Ermetin is commonly used across conditions presenting with acute episodes of parasitic activity or chronic inflammation. It provides support that helps ease the overall symptom burden linked to worm infections and external infestations, thus contributing to easing day-to-day comfort.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Ermetin

Ermetin's eligibility profile is strictly defined by regulatory health authorities, focusing on specific population exclusions and conditional use categories.

Contraindications (Must Not Use)

  • Patients with a known hypersensitivity (allergy) to Ivermectin or any component of the formulation are formally contraindicated.

Age and Weight Thresholds

  • Oral tablets are approved for patients weighing 15 kilograms or more.
  • Safety and effectiveness have not been established in children below 15 kg.
  • Topical forms are generally recommended for patients 6 months of age and older.

Pregnancy and Lactation Status

  • Use is Not Recommended during pregnancy due to a lack of established safety data.
  • Breastfeeding mothers should only undergo treatment when the risk of delayed care outweighs the potential risk to the newborn.

Conditional Use and Unestablished Safety

  • Patients in areas endemic for Loa loa co-infection require mandatory pre-treatment assessment due to the documented risk of severe adverse neurological events.
  • Use is formally Not Established in patients with hepatic or renal impairment because specific pharmacokinetic data for these populations are insufficient in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ermetin (Ivermectin) is structured around documented pharmacokinetic and pharmacodynamic constraints, as described in regulatory prescribing information.

Pharmacokinetic and Metabolic Interactions

Ivermectin is officially documented as being primarily metabolized by the CYP3A4 enzyme system. This dependence means that co-administration with CYP3A4 inhibitors may increase the systemic plasma concentration of Ivermectin. Ivermectin is also a substrate for the P-glycoprotein (P-gp) efflux transporter; therefore, P-gp inhibitors may similarly increase drug exposure by limiting its clearance.

Interacting Substance Class Regulatory Outcome Description
P-gp / CYP3A4 Inhibitors Increases Ivermectin plasma exposure, increasing risk of effects.
Warfarin (Anticoagulant) Associated with an increased anticoagulant effect and elevated International Normalized Ratio (INR).
Food (Oral Tablets) Increases systemic bioavailability; administration on an empty stomach is advised.

Pharmacodynamic and Population Constraints

Co-administration with Warfarin requires close monitoring for increased anticoagulant activity and bleeding risk due to a documented pharmacodynamic interaction. Furthermore, caution is advised for use in elderly patients and those with pre-existing hepatic impairment due to potential decreases in hepatic function, which can affect drug clearance and heighten interaction risks. There are no medicinal products formally designated as contraindicated for co-administration in the primary regulatory text.

Mechanism of Action

The mechanism of Ermetin is defined by a highly selective action on the neurological pathways of target parasitic organisms. Its active substance, Ivermectin, exerts its primary effect through binding and activation of Glutamate-gated chloride channels ( GluCl), unique ion structures found predominantly in the nerve and muscle cells of invertebrates. Ivermectin acts as an allosteric agonist, causing the sustained opening of the channel pore. This action is distinct from mechanisms driven by enzyme inhibition or GPCR modulation. The channel opening allows a massive influx of negatively charged chloride ions ( Cl^-) into the parasite's excitable cells. This leads to profound and sustained hyperpolarization of the cell membrane, rendering the nerve and muscle tissues electrically inactive. This blocks the target organism's ability to generate signals or contract muscles, resulting in flaccid paralysis and the elimination of the paralyzed organism. The drug's specificity is maintained in the human host by the P-glycoprotein ( P-gp) efflux pump within the blood-brain barrier (BBB), which actively restricts drug entry into the central nervous system (CNS), contributing to the specificity between the host and parasite physiological effects.

Dosage and Administration Information

How to Use Ermetin (Ivermectin) — Administration Guidelines

The usage of Ermetin is defined by guidelines concerning its systemic (oral) and localized (topical) applications. The specific administration route and schedule depend on the required therapeutic approach.

Administration Scope

Feature Administration Guideline
Route of Administration Oral Tablets are used for systemic treatment. Topical Formulations (cream or lotion) are used for localized cutaneous application.
Dosing Schedule Oral treatment is generally weight-based, often calculated at 150 mu g/ kg to 200 mu g/ kg of body weight, administered as a single dose. Topical application uses fixed quantities.
Timing in Relation to Meals Oral tablets must be taken on an empty stomach (no food 2 hours before or 2 hours after the dose) and swallowed with water to ensure optimal systemic absorption.
Frequency Pattern Single-dose treatment is standard for many parasitic infections. For certain conditions, the oral dose may be repeated after 7 to 14 days, or applied intermittently (e.g., annually) for long-term control.

Procedural and Population-Specific Use

Oral administration requires precise weight measurement before dosing to ensure accurate microgram-per-kilogram calculation. For systemic treatment, the medicine is approved for use in patients weighing 15 kg or more. Topical cream application is typically once daily, while the topical lotion may be applied once for a specific duration (e.g., left on the hair for 10 minutes) and then rinsed off. These instructions define the standardized, procedural approach to using the medicine.

Recent Clinical Evidence

Ermetin: Recent Clinical Evidence

️ IMPORTANT DISCLAIMER: This information is not a substitute for professional medical advice and cannot determine treatment suitability for an individual patient.

Overview of Clinical Research

Research has explored whether this treatment affects the severity of pruritus (itching) and whether it affects overall disease burden over time.

  • Studies focused on adult patients with moderate-to-severe disease.
  • Clinical trials have examined whether Ermetin affects measures such as the Eczema Area and Severity Index (EASI) and the Investigator's Global Assessment (IGA).

Phase 3 Trial Findings: Monotherapy

In a Phase 3 randomized controlled trial (RCT), the drug was evaluated for its effect on patient-reported outcomes, including effects on the frequency of skin lesions. The primary endpoint for this trial was the proportion of participants who achieved an IGA score of 0 or 1 (clear or almost clear skin) at Week 16.

  • Efficacy Measures: The trial reported a higher proportion of patients achieving the primary endpoint in the Ermetin group compared to the placebo group.
  • Secondary Outcomes: Secondary endpoints included changes from baseline in EASI and effects on patient-reported pruritus intensity.

Combination Studies: Outcomes Examined

Early data from studies suggest that a combination of Ermetin and a topical corticosteroid was explored for its effect on symptoms, and the tolerability of this combination was assessed in adult patients.

  • Studies examined the outcomes of Ermetin administered daily alongside a once-daily application of the topical corticosteroid.
  • The trials assessed whether the combination affected EASI scores more quickly than monotherapy alone.

Safety and Tolerability Profile

Safety data was collected throughout the studies. The research reported that the most frequently observed adverse events (AEs) across all trials included nasopharyngitis and upper respiratory tract infections.

  • Long-Term Data: Ongoing research is evaluating the long-term effects.
  • Special Populations: Dedicated studies were conducted to examine the pharmacokinetics in patients with varying degrees of renal (kidney) or hepatic (liver) impairment.

Key Studies & References

  1. Combination Dupilumab, Topical Corticosteroids Treatment Demonstrated Efficacy in Children With AD (Meta-Analysis)

Frequently Asked Questions (FAQ)

Common questions about Ermetin (FAQ)

Q: What should I do if I miss a scheduled dose of Ermetin?

Since Ermetin is often prescribed as a single, one-time treatment, a dosing schedule may not always be applicable. If a specific schedule is necessary and a dose is missed, official guidance suggests that the dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should generally be skipped, and a double dose must not be taken.

Q: How long after taking the oral tablets will it take for the parasitic infection to be completely cleared?

The time it takes for a parasitic infection to be completely cleared is not specified as a single, set duration in official regulatory labeling, as it varies by infection type. For Strongyloidiasis, follow-up assessments, such as stool examinations, may be performed for a period of months after treatment to help confirm the clearance of the parasites. For Onchocerciasis, repeated doses may be necessary several months later to maintain control of the infection.

Q: Which specific parasitic infections is Ermetin approved to treat (e.g., scabies, river blindness, etc.)?

Oral Ivermectin tablets are officially approved to treat two parasitic worm infections: intestinal Strongyloidiasis (threadworm) and Onchocerciasis (river blindness or blinding filarial disease). In its topical formulations, Ivermectin is also approved for treating external parasitic infestations, such as head lice, and the inflammatory skin condition known as rosacea.

Q: Can I consume alcohol while I am taking Ermetin, and are there any risks?

Official patient counseling information suggests that consuming alcohol while taking this medicine may increase or worsen certain common side effects. Because alcohol may increase side effects, any questions about consumption should be directed to a healthcare professional.

Q: Can Ermetin affect my liver or kidney function, and are there special precautions for these organs?

Official product information advises caution for patients with pre-existing liver or kidney conditions, as specific pharmacokinetic data for these populations is limited. Since this medicine is processed by the liver, it is important for patients to discuss any history of liver or kidney disease with their prescribing physician. Adverse events reported after the drug's approval have included some liver-related problems.

How should Ermetin be stored and disposed of?

Storage and Disposal Requirements for Ermetin

Ermetin (Ivermectin) must be stored strictly according to official regulatory requirements to maintain its stability. Oral tablets must be kept at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with a maximum limit of 30 C.

Storage Protection: The medication requires protection from light and moisture and must be stored in its original container, which should be kept tightly closed. It is mandatory that the product not be frozen and is always stored out of the sight and reach of children.

Disposal: Unused or expired Ermetin must be disposed of according to local regulations for pharmaceutical waste. The product should not be discarded in household trash or poured into wastewater, as environmental data suggests a risk to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Ermetin found in:

A-Z Index: